Physician profile
Lory E Baraz
NPI 1790780393
$10,465.24
in general payments reported to CMS, 2019-2025
56 companies · $1,140 in 2025
The $1,140 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,588 · 2020: $956 · 2021: $1,961 · 2022: $1,604 · 2023: $1,735 · 2024: $1,482 · 2025: $1,140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,259 · Education: $96.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,259.28 |
| Education | $96.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,091.51 | 2019-2025 | Creon, Synthroid, Linzess |
| Lilly USA, LLC | $1,054.60 | 2019-2025 | Jardiance, Mounjaro, Humulin |
| Novo Nordisk INC | $966.14 | 2020-2024 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $707.89 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2, Proclaim |
| Astrazeneca Pharmaceuticals LP | $660.14 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $452.65 | 2020-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $391.89 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $382.51 | 2019-2024 | |
| Amneal Pharmaceuticals LLC | $362.23 | 2019-2025 | Unithroid |
| Amgen INC. | $361.60 | 2019-2025 | Evenity, Prolia, Tepezza |
| Mannkind Corporation | $345.55 | 2019-2024 | Afrezza |
| Xeris Pharmaceuticals, INC. | $315.18 | 2021-2025 | Recorlev |
| Radius Health, INC. | $305.72 | 2019-2025 | Tymlos |
| Horizon Therapeutics Plc | $240.60 | 2021-2023 | Tepezza |
| Merck Sharp & Dohme LLC | $201.72 | 2019-2023 | Steglatro |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lory Baraz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.